缬沙坦及苯那普利对5/6肾切除大鼠肾小球硬化的影响

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (8): 914-918.

缬沙坦及苯那普利对5/6肾切除大鼠肾小球硬化的影响

杨利才, 张道友, 章辉, 朱桂岚, 高潮清

皖南医学院弋矶山医院肾内科, 芜湖241001, 安徽

收稿日期:2004-04-28 修回日期:2004-07-13 出版日期:2004-08-26 发布日期:2020-11-20
通讯作者: 杨利才,男,医学硕士,研究方向为肾脏病基础与临床。Tel:0553-5739317 E-mail:yanglicai2003@yahoo.com.cn
作者简介:张道友,男,主任医师,教授,硕士研究生导师,研究方向主要为肾脏病基础与临床。Tel:0553-5739317

Effects of valsartan and benazepril on glomerulosclerosis in rats with 5/6 nephrectomy

YANG Li-Cai, ZHANG Dao-You, ZHANG Hui, ZHU Gui-Lan, GAO Chao-Qing

Department of Nephrology, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2004-04-28 Revised:2004-07-13 Online:2004-08-26 Published:2020-11-20

摘要/Abstract

摘要： 目的: 观察并比较缬沙坦及苯那普利对5/6肾切除大鼠肾小球硬化的改善作用,探讨其作用机制。方法: 选用SD 雄性大鼠30 只,通过5/6 肾切除法制造慢性肾功能衰竭模型,术后2 周随机分为模型组、缬沙坦组及苯那普利组,并设假手术组作为对照。术后第6 周末各组大鼠进行体重、血压、血清肌酐(Scr)及尿素氮(BUN)的测定,处死大鼠,取出肾组织进行病理组织形态学观察,并采用免疫组织化学方法检测肾组织转化生长因子β₁(TGF-β₁)、IV 型胶原、纤维连接蛋白(FN)表达。结果: 同模型组相比,两治疗组收缩压下降(P均<0.01),肾功能改善;肾小球系膜增殖程度、肾小球硬化指数(GSI)降低(P均<0.01);免疫组化染色显示,两治疗组肾小球转化生长因子β₁(TGF-β₁)、纤维连接蛋白(FN)及IV 型胶原表达均较模型组下降(P均<0.01)。结论: 缬沙坦及苯那普利对慢性肾功能衰竭大鼠具有同等的肾脏保护作用;改善肾小球硬化是通过减少肾小球TGF-β₁ 表达,从而减少FN 及IV 型胶原生成来实现的。

关键词: 血管紧张素转化酶抑制剂, 血管紧张素受体拮抗剂, 肾小球硬化, 转化生长因子β₁, 细胞外基质

Abstract: AIM: To observe and compare the improvement of glomerul-osclerosis in rats with 5/6 nephrectomy by valsartan and benazepril.METHODS: Thirty Sprague-Dawley male rats were selected and performed five-sixths nephrectomy to produce chronic renal failure model.Two weeks after the surgery, the rats were randomly divided into model group, valsartan group and benazepril group, and established a shame group serving as normal control.The weight, blood pressure, blood uria nitrogen (BUN) and serum creatinine were measured on the sixth week after operation, then the rats were killed to take the kidneys for pathological histological observation. Immunohistochemistry was used to examine the expression of TGF-β₁ protein and fibronectin (FN) and collagen IV in glomeruli.RESULTS: As compared with model group, systolic pressure decreased (P<0.01) and renal function was ameliorated in two treatment groups, as well as the extent of glomerular mesangial proliferation, glomerulosclerosis index (GSI) decreased significantly (P<0.01).Immunohistochemistry staining indicated that there was an decreasing expression of TGF-β₁, FN and collagen IV in glomeruli in two treatment groups compared with model group (P<0.01).CONLUSION: The renoprotective effect of valsartan on chronic experiment renal failure rats is similar as benazepril.valsartan and benazepril can improve glomerulosclerosis by decreasing the expression of TGF-β₁, FN and collagen IV in glomeruli.

Key words: angiotensin converting enzyme, angiotensin receptor antagonist, glomerlosclerosis, transforming growth factorβ₁, extracellular matrix

中图分类号:

R965.1

杨利才, 张道友, 章辉, 朱桂岚, 高潮清. 缬沙坦及苯那普利对5/6肾切除大鼠肾小球硬化的影响[J]. 中国临床药理学与治疗学, 2004, 9(8): 914-918.

YANG Li-Cai, ZHANG Dao-You, ZHANG Hui, ZHU Gui-Lan, GAO Chao-Qing. Effects of valsartan and benazepril on glomerulosclerosis in rats with 5/6 nephrectomy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 914-918.

参考文献

1 Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, et al.Effects of Candesartan cilexetil (TCV-116) and enalapril in 5 6 nephrectomized rats[J].Kidney Int, 1997;52(suppl63):136-9
2 Lacourciere Y, Belarger A, Godin C, Halle JP, Ross S, Wright N, et al.Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy[J].Kidney Int, 2000;58(2):762-7
3 Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin Ⅱ receptor blockade in type I diabetic patients with diabetic nephropathy[J].Kidney Int, 2000;57(2):601-6
4 Raij L, Azar S, Keane W.Mesangial immune injury, hypertension, and progressive glomerular damage in dah1 rats[J].Kidney Int, 1984;26(2):137-43
5 邹万忠.肾活检病理图鉴[M].北京:人民卫生出版社,2000:55
6 Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E, et al.Glomeruloscerosis induced by in vivo transfection of transforming growth factor or platelet-derived growth factor gene into the rat kidney[J].J Clin Inest, 1993;92(6):2597-603
7 Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al.Functional and biochemical analysis of angiotensinⅡ-forming pathways in the human heart[J].Circ Res, 1997;80(2):219-27
8 Schmitz D, Berk BC.Angiotensin Ⅱ signal transduction stimulation of mutiple mitogen activated protein kinase pathways[J]. Trends EndocrinolMetab, 1997;8(2):261-6
9 Kagami S, Border WA, Miller DE, Noble NA.Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells[J].J Clin Invest, 1994;93(6):2431-7
10 黄洁, 李一石, 孙兴昌.依贝沙坦与苯那普利治疗原发性高血压比较[J].中国临床药学志, 2001;10(2):205-7
11 Obata J, Nakamura T, Kuroyanagi R, Yoshida Y, Guo D, Inagami T, et al.Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats[J].Kidney Int, 1997;52(suppl 63):229-31
12 Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H.Blocking angiotensin Ⅱ ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis[J].Kidney Int, 1999;55(3):877-89
13 Enz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M. Valsartan, a new angiotensin Ⅱ receptor antagonist :a doubleblind study comparing the incidence of cough with lisinopril and hydrochlorothiazide[J].J Clin Pharmacol, 1997;37(2):101-7

[1]	陈佳，刘青武，何秀娟，李萍. 细胞外基质在皮肤创面修复中的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(6): 716-720.
[2]	周露萍, 陈露露, 周宏灏, 欧阳冬生. IV型胶原蛋白与肾脏疾病[J]. 中国临床药理学与治疗学, 2015, 20(9): 1060-1065.
[3]	王增, 袁梅琴, 杨国浓, 丁海樱. ACEI/ARB类降压药物在肿瘤治疗中的临床研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 230-234.
[4]	张敏, 曹述任. 丹酚酸B对转化生长因子β₁诱导人肺成纤维细胞增殖和分化的影响[J]. 中国临床药理学与治疗学, 2014, 19(10): 1081-1086.
[5]	韩素芳. 血管紧张素转换酶抑制剂联合血管紧张素II受体拮抗剂对糖尿病肾病肾功能临床疗效的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(11): 1257-1262.
[6]	伍艳. 血管紧张素转化酶抑制剂加钙离子拮抗剂联合用药治疗模式对于轻、中度原发性高血压的临床疗效观察及其对血尿酸水平的影响[J]. 中国临床药理学与治疗学, 2011, 16(3): 317-321.
[7]	廖梅梅, 熊世熙, 肖然, 闵新文, 杨汉东. 血管紧张素转化酶抑制剂改善糖尿病大鼠心肌间质重构的类效应研究[J]. 中国临床药理学与治疗学, 2009, 14(1): 62-66.
[8]	栾旭. 血管紧张素转换酶抑制剂联合血管紧张素II受体阻滞剂治疗糖尿病肾病的临床研究[J]. 中国临床药理学与治疗学, 2006, 11(6): 706-708.
[9]	薛浩, 高敏, 刘国树, 汪海. 盐酸埃他卡林对自发性高血压大鼠肾组织细胞外基质降解系统的影响[J]. 中国临床药理学与治疗学, 2006, 11(10): 1122-1128.
[10]	梁绪国, 张岫美. 血管紧张素转化酶抑制剂与血管紧张素受体拮抗剂合用对腹主动脉狭窄高血压大鼠心肌肥厚的影响[J]. 中国临床药理学与治疗学, 2006, 11(10): 1133-1136.
[11]	刘淑华, 张黎军, 刘昌慧, 王绍华. 氯沙坦对TGF-β₁ 在自发性高血压大鼠肾小管表达的影响及作用[J]. 中国临床药理学与治疗学, 2005, 10(2): 145-149.
[12]	武多娇, 洪华山. 心肌纤维化药物治疗的研究进展[J]. 中国临床药理学与治疗学, 2004, 9(12): 1327-1332.
[13]	周爱玲, 罗琳, 茅家慧, 朱燕. 苦参素对实验性肝纤维化的防治作用及对MMP-2 表达的影响[J]. 中国临床药理学与治疗学, 2004, 9(10): 1096-1100.
[14]	王军, 程晓霞, 杨汝春, 朱晓玲, 鲁盈, 王永钧. 复方积雪草对局灶硬化性肾小球肾炎模型小鼠肾组织内细胞因子表达的调控作用[J]. 中国临床药理学与治疗学, 2003, 8(6): 638-641.
[15]	叶敏利, 李庆平. 姜黄素对心脏压力过负荷大鼠主动脉细胞外基质的影响¹[J]. 中国临床药理学与治疗学, 2003, 8(2): 125-128.